The Company anticipates full-year 2025 total revenue of $732M, reflecting growth of approximately 20% compared to the full-year 2024. This includes surgical revenue of approximately $657M and approximately $75M of EOS revenue. The Company also expects adjusted EBITDA of approximately $75M, which will contribute to positive free cash flow for the full-year 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.